PTH and nephrocalcinosis: Interestingly, in patients treated with disothiazide (used in cases of hypercalciuria and nephrocalcinosis), serum calcium level decreased (10.5 ± 0.5–10.3 ± 0.4 mg/dL, p = 0.050), PTH level did not significantly change (x1.6 ± 0.7 to x1.7 ± 0.8, p = 0.400), and the rates of osteoporosis, fractures, and death were 17/23 (74.0%), 11/23 (48.0%) and 2/23 (9.0%), respectively [24].